Member Info for surprised

https://twitter.com/surprised_trade/status/1453281499701207047

Cash remain strong at A$2.7m with no debt and our R&D tax rebate of A$3.2m is expected in the next 8 weeks, Q1 sales have again been strong, up 25% CAP-XX production line has increased output by over 25%

https://twitter.com/surprised_trade/status/1453303453837561863

court case re Maxwell/Tesla infringed patent due for mediation talks in a few weeks, business is growing as below with own production line etc. IF Maxwell/Tesla infringed then likely large costs to #CPX if not infringed no change as business still growing etc.

Cenkos broker note -We maintain our DCF valuation of 15p at 13% discount rate with the potential for this to increase significantly as confidence in its path to profitability increases. Our valuation leaves upside from more licensees, including a potential result against Maxwell/Tesla, greater long-term market share than 5%, as well as the potential for greater growth in supercapacitor demand from IOT than assumed based on market forecasts

https://*********************/companies/uk/electronic-products/cap-xx-limited/research/cenkos-securities/cenkos-cap-xx-ltd-fy22-off-to-a-good-start/39_042b7c1f-9e50-4a3e-8a21-a7951c79f38a

https://twitter.com/surprised_trade/status/1453283418926690310

IC have revised target up to 164p RNS - capital return and divii pymnt, bonus to holders who own stock on 12.11.21 , pymt due 8.12.21

the Company intends to return an amount to shareholders of approximately A$5.6 million, consisting of a return of share capital of approximately A$4.76 million by way of a capital reduction to be effected by the Company paying up to 4.4618 cents per share (or depositary interest) and an unfranked dividend of approximately A$0.84 million being 0.7874 cents per share (or depositary interest), to each registered holder of the shares as at the proposed record date of 5:00pm (GMT) on Friday, 12 November 2021 with payment expected to be made on 8 December 2021. At the date of this notice, the Group has approximately A$13 million of cash or cash equivalents.

https://*********************/newsfeed/article/thinksmart-limited-capital-return-and-dividend-and-notice-of-agm-1285004

https://twitter.com/surprised_trade/status/1453252135324373002

.acquisition of Document Warehouse business, including warehouse and logistics centre..

https://twitter.com/surprised_trade/status/1452906336170217473

Autumn budget: billions more for NHS in bid to tackle backlog...TLY provides solutions to the healthcare sector.

Liontrust Investment Partners increase holding in TLY to 5.24 % on 28.9.21 .....TLY awarded £16m & £22m contract extensions in last 4 weeks

https://twitter.com/surprised_trade/status/1452529294270418950

Autumn budget: billions more for NHS in bid to tackle backlog

Liontrust Investment Partners increase holding in TLY to 5.24 % on 28.9.21 .....TLY awarded £16m & £22m contract extensions in last 4 weeks.

https://www.thetimes.co.uk/article/autumn-budget-2021-nhs-rishi-sunak-59slvhtjf

Autumn budget: billions more for NHS in bid to tackle backlog

https://twitter.com/surprised_trade/status/1452198502361145356

Hydrogen cars and boilers spark hopes of a green revolution

Hydrogen is the gas of the moment and will be all the rage in the talking shops of the Cop26 summit.

https://www.thetimes.co.uk/article/hydrogen-cars-and-boilers-spark-hopes-of-a-green-revolution-bvlvclcng

https://twitter.com/surprised_trade/status/1450779698913554432

broker note target price 80p

flushing out those who feel this is not cheap down here etc. still holding all mine (shares !) as to me sp has been taken down considerably..broker notes both suggest much greater upside from these levels with fair value between 61p and 80p...as ever in these situations, that many companies are experiencing now, the initial drop is somewhat overdone...toilet paper is not a hobby and therefore is still in everyday demand ( great post Mr casual lol) and with the bod's experience and own paper mill upcoming it appears the sp could indeed recover over coming days/weeks as the business is in shape from all accounts to build from here

Liberum broker note..20.10.21
...Accrol remains fundamentally strong after significant progress in FY’21 The business remains in excellent operational shape with scalable foundations for growth and a strong market position across UK retail. Acquisitions of LTC and John Dale in FY’21 have provided the company with further scale, complementary new customers, synergies in distribution costs, spare capacity and entry into the complimentary adjacent category of fully flushable wet wipes. Accrol completed the full automation of the Blackburn tissue plant in FY’21, with robotisation replacing all manual finished goods movements. The four converting lines at the LTC plant are already fully automated. With a small element of automation to be completed in Leyland in FY’22E, as a new machine arrives, the Group will have three fully automated greenfield sites to achieve the lowest possible operational cost base in the UK. The group has no further significant capital requirements for the Tissue Converting division.

Accrol’s has made significant advancement on its plan to develop its own paper mill. It has finalised the specifications and costs of the machine and the building and is currently running a selection process for the mill’s location. This machine will be a UK leader in efficiency, quality and carbon neutrality. The machine, once completed, will fulfil half of the business’s current tissue requirements. The company is mindful of the current energy costs and their impact on the feasibility of the mill investment, and it will look to secure a long-term energy supply contract, as well as explore options for on-site energy generation before committing to the investment in the mill. No additional funding is expected to be required from shareholders to deliver this investment.

Valuation appears cheap at 7x CY’22E EV/EBITDA Target Price to 80p to reflect lowered forecasts.

https://twitter.com/surprised_trade/status/1451440917806788648

broker note out with target price 260p

....On the data monetisation side, advertising spend using Bango Marketplace is surging across multiple verticals. It is clear to us that the significant revenue and earnings upside from investments made in the past are starting to come through. The recent pullback in the share price further increases the attractiveness of the stock. Strong Buy reiterated

...The company is also in discussions with another five major telcos, which if converted into firm contracts could result in an equivalent recurring revenue. With Bango’s unique offering and growing relationships with OTT providers and telcos, we would expect this segment to be a strong growth area for the business for many years to come.

we're back in witchcraft land on the techs, rsi 30 (oversold) and interestingly a a couple of months ago a few folk invested £3m quid in CPX at 5.5p in the fund raise...they have not had a return on that as the sp has remained stubbornly below since.....cheap can always go a bit cheaper, equally cheapcan be seen to provide a fabulous opportunity below the 5.5p ....I topped up yet more at 5.39p a few weeks ago on the basis I was on the right side of the placing price and clearly with a £3m investment all will be seeking a decent return...the news flow for such an investment clearly has not begun.....yet :-)

ACRL highlighted in the Times today.....

Accrol said: “In line with the wider market, pressures on the group’s raw material supply chains have been considerable, with further tightening in recent weeks.”
The news sent shares in Accrol down by more than 13 per cent, or 6p, to 39p last night, their lowest level since April last year. While the group’s supply chain has shown significant resilience and supply shortages have been managed, considerable cost increases had to be absorbed in the short term,

Accrol said yesterday that it was now “targeting only higher-value business” and was “avoiding long-term, fixed-price agreements” to ensure that “revenue growth is of good quality”. It said that “short-term external challenges facing the business have no effect on the ongoing execution of the group’s strategy . . . The business remains in excellent operational shape.

Liberum, which acts as a broker on behalf of Accrol, said that while the tissue maker had “seen very substantial cost increases over the last six months”, the business was “in a structurally much stronger position to deal with these pressures than at any time in the past” and that the shares offered strong value.

Tom Fraine and Clive Black, of Shore Capital, said: “We believe the business is doing the right things in terms of mix, cost-control and price recovery in markets where transparent supply constraints are proving challenging for all to manage.” They said that beyond the present pressures there was a “well-invested and resilient everyday business with bright prospects”.

https://www.thetimes.co.uk/article/accrol-feels-pain-of-rising-costs-and-driver-shortage-37p3xm78v

https://twitter.com/surprised_trade/status/1450779698913554432

second broker note out

Second broker, Liberum, note out -
Accrol remains fundamentally strong after significant progress in FY’21

The business remains in excellent operational shape with scalable foundations for growth and a strong market position across UK retail. Acquisitions of LTC and John Dale in FY’21 have provided the company with further scale, complementary new customers, synergies in distribution costs, spare capacity and entry into the complimentary adjacent category of fully flushable wet wipes. Accrol completed the full automation of the Blackburn tissue plant in FY’21, with robotisation replacing all manual finished goods movements. The four converting lines at the LTC plant are already fully automated. With a small element of automation to be completed in Leyland in FY’22E, as a new machine arrives, the Group will have three fully automated greenfield sites to achieve the lowest possible operational cost base in the UK. The group has no further significant capital requirements for the Tissue Converting division. Accrol’s has made significant advancement on its plan to develop its own paper mill. It has finalised the specifications and costs of the machine and the building and is currently running a selection process for the mill’s location. This machine will be a UK leader in efficiency, quality and carbon neutrality. The machine, once completed, will fulfil half of the business’s current tissue requirements. The company is mindful of the current energy costs and their impact on the feasibility of the mill investment, and it will look to secure a long-term energy supply contract, as well as explore options for on-site energy generation before committing to the investment in the mill. No additional funding is expected to be required from shareholders to deliver this investment.

Valuation appears cheap at 7x CY’22E EV/EBITDA

Our Target Price 80p (from 95p) to reflect lowered forecasts.

Btroker note out ....

Impact on forecasts: As a result of this update, we now anticipate FY22E revenues to grow by c.25% YOY

We expect profitability to be significantly H2 weighted given the immediate cost pressures versus the time lag

Investment view:
Accrol trades on a FY22E PE of 16.5x falling to 10.9x in FY23E. A rerating of Accrol to 15.0x-16.0x FY23E PE (in line with listed peer average) implies a valuation of 61.0p – 66.1p, implying upside of 38% to 47% versus last nights close.

Intrinsic value
Based on the average FY2 P/E of the Group’s listed peers, a rerating of Accrol to 15.0x – 16.0x FY23E P/E implies a valuation of 61.0p – 66.1p, equating to upside of 38% to 47%. We believe the Group in its current form can generate revenue of c.£250m and EBITDA in excess of £35.0m over the medium term. Profitability could be boosted further through the development of its planned paper mill, with an update on its status expected at Interim Results. We believe the addition of a paper mill would drive gross margin towards 33%, with EBITDA margins at c.18%. On this basis the Group would be capable of delivering EBITDA in the region of £45.0m, implying significant uplift versus current levels and driving a material improvement in shareholder value.

https://*********************/companies/uk/household-goods/accrol-group-holdings-plc/research/zeus-capital/accrol-group-holdings-plc-acrl-ln-trading-update/92fa8f66-49ba-41ec-be24-c135d0a75b6a/bbece8f1-36a0-495c-9093-f3cae5555a26

Lol,..I'll let the first whippings land and see how it feels after the first hard blows....the initial wounds are likely to heal up in a day or two...

it's a rare bb that has more non holders posting than those who own shares, lol....I appreciate there is a 'war of words' taking place on the bb between various posters intent on bashing each others investments on the respective bb's, however, for what it's worth...
I like the potential ahead for TLY, clearing NHS backlogs, they are many and very long....a couple of decent contract extensions of 16 million and 22 million quid is not a bad start and in one of those strange twists the sp fell away following the good news....as we know the fundamentals and the sp can be become detached at times and this appears to be one of those moments....depending on an investors view point, it may be seen by some as an opportunity ...Lion Trust Investment, with their team of researchers, increased their holding in TLY from 4.7 percent to 5.24 percent on 28.09.21....seems I'm not alone in seeing potential ahead, despite short term volatility :-)

Hi Nate, with respect, it's a bit more nuanced than selling or buying shares...folk do not just buy shares if a staff member buys, equally someone selling shares can be because a a myriad of reasons and not a reason to follow.... there's a bigger picture imo

straight to nt :-)

https://twitter.com/surprised_trade/status/1448535838812409856

capital return and divii pymnt, bonus to holders who own stock on 12.11.21 , pymt due 8.12.21

IC have revised target up to 164p

ThinkSmart Limited (AIM: TSL), a specialist digital payments platform business, announces the intention to return approximately A$5.6 million to shareholders.

Subject to shareholder approval at the Company's 2021 Annual General Meeting ("AGM"), the Company intends to return an amount to shareholders of approximately A$5.6 million, consisting of a return of share capital of approximately A$4.76 million by way of a capital reduction to be effected by the Company paying up to 4.4618 cents per share (or depositary interest) and an unfranked dividend of approximately A$0.84 million being 0.7874 cents per share (or depositary interest), to each registered holder of the shares as at the proposed record date of 5:00pm (GMT) on Friday, 12 November 2021 with payment expected to be made on 8 December 2021. At the date of this notice, the Group has approximately A$13 million of cash or cash equivalents.